Skip to main content
SpringerLink
Log in

Pulmonary Hypertension

  • Chapter
  • First Online:
MGH Cardiology Board Review

  • 3167 Accesses

Abstract

The right ventricular-pulmonary vascular unit is a low resistance, high compliance system that is normally capable of accommodating large increases in blood flow with a minimal increment in pressure. The development of elevated pulmonary arterial pressures, either in unselected populations or in individuals with a variety of cardiopulmonary diseases, is increasingly recognized to be associated with a markedly increased risk of mortality. Regardless of the etiology, pulmonary hypertension leads to right ventricular dysfunction that is closely associated with impaired exercise capacity, renal and hepatic dysfunction. This chapter will briefly review the epidemiology and pathophysiology of pulmonary hypertension (PH) in addition to current diagnostic and treatment approaches with particular emphasis on PH arising in the setting of other cardiovascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

6 MW:

6 Minute Walk

APAH:

Associated with Pulmonary Arterial Hypertension

BMP:

Bone Morphogenic Protein

CCB:

Calcium Channel Blockers

COPD:

Chronic Obstruction Lung Disease

CTEPH:

Chronic Thromboembolic Pulmonary Hypertension

DVT:

Deep Venous Throbosis

FPAH:

Familial Pulmonary Arterial Hypertension

HFpEF:

Heart Failure with preserved Ejection Fraction

IPAH:

Idiopathic Pulmonary Arterial Hypertension

JVP:

Jugular Venous Pressure

LFT:

Liver Function Test

LVEF:

Left Ventricular Ejection Fraction

mPAP:

Mean Pulmonary Artery Pressure

NO:

Nitric Oxide

NYHA:

New York Heart Association

PA:

Pulmonary Artery

PAH:

Pulmonary Arterial Hypertension

PAP:

Pulmonary Artery Pressure

PCH:

Pulmonary Capillary Hemangiomatosis

PCWP:

Pulmonary Capillary Wedge Pressure

PDE-5:

Phosphodiesterase-5

PE:

Pulmonary Embolism

PH:

Pulmonary Hypertension

PVOD:

Pulmonary Veno-Occlusive Disease

PVR:

Pulmonary Vascular Resitance

RV:

Right Ventricle

RVEF:

Right Ventricular Ejection Fraction

TAPSE:

Tricuspid Annular Plane Systolic Excursion

TTE:

Transthoracic echocardiogram

WHO:

World Health Organization

References

  1. McLaughlin VV, Archer SL, Badesch DB, Barst RB, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. J Am Coll Cardiol. 2009;53:1573–619.

    Article  PubMed  Google Scholar 

  2. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol. 2002;40:780–8.

    Article  PubMed  CAS  Google Scholar 

  3. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76–81.

    Article  PubMed  CAS  Google Scholar 

  4. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–11.

    Article  PubMed  CAS  Google Scholar 

  5. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–30.

    Article  PubMed  Google Scholar 

  6. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343–9.

    Article  PubMed  Google Scholar 

  7. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44–54.

    Article  PubMed  CAS  Google Scholar 

  8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.

    Article  PubMed  CAS  Google Scholar 

  9. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915–22.

    Article  PubMed  CAS  Google Scholar 

  10. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60:1025–30.

    Article  PubMed  CAS  Google Scholar 

  11. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–26.

    Article  PubMed  Google Scholar 

  12. Tadalafil (Adcirca) for pulmonary arterial hypertension. Med Lett Drugs Ther. 2009;51(1324):87–8.

    Google Scholar 

  13. Behling A, Rohde LE, Colombo FC, et al. Effects of 5’-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail. 2008;14:189–97.

    Article  PubMed  CAS  Google Scholar 

  14. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–9.

    Article  PubMed  CAS  Google Scholar 

  15. Centers for Disease Control and Prevention. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension—seven sites, United States, 2003–2006. MMWR Morb Mortal Wkly Rep. 2007;56:170–2.

    Google Scholar 

  16. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172:1586–9.

    Article  PubMed  Google Scholar 

  17. Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail. 2002;8:124–7.

    Article  PubMed  Google Scholar 

  18. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189–94.

    Article  PubMed  Google Scholar 

  19. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866–70.

    Article  PubMed  CAS  Google Scholar 

  20. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.

    Article  PubMed  Google Scholar 

  21. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127:1531–6.

    Article  PubMed  Google Scholar 

  22. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;166:1555–62.

    Article  Google Scholar 

  23. Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136–44.

    Article  PubMed  CAS  Google Scholar 

  24. Butler J, Chomsky DB, Wilson JR. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol. 1999;34:1802–6.

    Article  PubMed  CAS  Google Scholar 

  25. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic ­thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257–64.

    Article  PubMed  CAS  Google Scholar 

  26. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149:521–30.

    Article  PubMed  Google Scholar 

  27. Fattouch K, Sbraga F, Bianco G, et al. Inhaled prostacyclin, nitricoxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg. 2005;20:171–6.

    Article  PubMed  Google Scholar 

  28. Theodoraki K, Tsiapras D, Tsourelis L, et al. Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand. 2006;50:1213–7.

    Article  PubMed  CAS  Google Scholar 

  29. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–4.

    Article  PubMed  Google Scholar 

  30. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27:589–95.

    Article  PubMed  CAS  Google Scholar 

  31. Galiè N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.

    Article  PubMed  Google Scholar 

  32. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.

    Article  PubMed  Google Scholar 

  33. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183–8.

    Article  PubMed  CAS  Google Scholar 

  34. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296–302.

    Article  PubMed  CAS  Google Scholar 

  35. Chatterjeee N, Lewis G. What is the prognostic significance of pulmonary hypertension in heart failure? Circ Heart Fail. 2011;4:541–5.

    Article  Google Scholar 

  36. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisenten for the treatment of pulmonary asterial hypertension: Result of the Ambrisenten in Pulmonary Arterial Hypertension, Randomized, Double-Blind, place to controlled Multicenter, Efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010–9.

    Google Scholar 

  37. Tedford RJ, Hemmes AR, Russell SD, et al. PDE5 inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1:213–219.

    Google Scholar 

  38. Guazzi M, Vilenzi M, Arga R, et al. Pulmonary Hypertension in the Heart Failure with Preserved Ejection Fraction. Circulation. 2011;124:164–174.

    Google Scholar 

  39. Hoeper MM, Mayer E, Simonneau G, et al. Chronic Thromboemboric Pulmonary Hypertension. Circulation. 2006;113:2011–20.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

    Jonathan Clarke MD (Clinical and Research Fellow)

  2. Mass General Cardiopulmonary Exercise Laboratory, Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

    Gregory D. Lewis MD (Assistant Professor of Medicine)

  3. Harvard Medical School, Boston, USA

    Gregory D. Lewis MD (Director)

Authors
  1. Jonathan Clarke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory D. Lewis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory D. Lewis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cardiology Division Yawkey Building 5B, Room 5850, Massachusetts General Hospital, Boston, Massachusetts, USA

    Hanna K. Gaggin

  2. Cardiology Division Yawkey Building, Suite 5984, Massachusetts General Hospital, Boston, Massachusetts, USA

    James L. Januzzi, Jr.

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Clarke, J., Lewis, G.D., Lewis, G.D. (2014). Pulmonary Hypertension. In: Gaggin, H., Januzzi, Jr., J. (eds) MGH Cardiology Board Review. Springer, London. https://doi.org/10.1007/978-1-4471-4483-0_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4483-0_22

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4482-3

  • Online ISBN: 978-1-4471-4483-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation